Release form: injection
Active ingredient: choline alphoscerate;
1 ml of the solution contains choline alphoscerate 250 mg;
Acute period of severe craniocerebral trauma with predominantly stem damage level (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brainstem damage).
Degenerative-involutionary brain psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, that is, primary and secondary mental disorders in older people characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased ability to concentrate; Changes in the emotional sphere and behavior: emotional instability, irritability, indifference to the environment; Pseudomelanchia in the elderly.